

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024

(Rs. in Lakhs)

	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended	9 months ended	9 months ended	Year ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
1	Revenue from operations	94942	101077	80526	277484	252391	345371
2	Other income	3507	3454	2811	10525	9276	12259
3	Total Income (1+2)	98449	104531	83337	288009	261667	357630
	Expenses						
	(a) Cost of materials consumed	9748	14896	9095	38467	34057	54517
	(b) Purchases of stock-in-trade	16423	21674	16252	55371	59734	85308
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	9745	1879	6337	10054	2949	(6372)
	(d) Employee benefits expense	12474	15071	14135	42673	45156	62439
	(e) Finance costs	9	27	32	73	103	180
	(f) Depreciation and amortisation expense	1880	1686	1711	5207	5158	6968
	(g) Other expenses	17360	15386	12901	46502	45352	58610
4	Total expenses	67639	70619	60463	198347	192509	261650
5	Profit before exceptional items and tax (3-4)	30810	33912	22874	89662	69158	95980
6	Exceptional items [credit/ (charge)] (Refer Note 2)	-	469	(16331)	469	(14601)	(14361)
7	Profit before tax (5+6)	30810	34381	6543	90131	54557	81619
8	Tax expense						
	(a) Current tax	7349	9876	3141	23581	17592	23759
	(b) Deferred tax	473	(745)	(1170)	79	(2583)	(1136)
9	Profit for the period/year (7-8)	22988	25250	4572	66471	39548	58996

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024

(Rs. in Lakhs)


	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended	9 months ended	9 months ended	Year ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
10	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss	157	-	(466)	157	(466)	(557)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(39)	-	118	(39)	118	140
11	Total comprehensive income for the period (9+10)	23106	25250	4224	66589	39200	58579
12	Total comprehensive income for the period attributable to owners of the Group	23106	25250	4224	66589	39200	58579
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941	16941	16941
	Other equity						160823
	Earnings per share (EPS) (of Rs. 10 each)						
	Basic and diluted EPS before Exceptional items (Rs.)	13.57	14.67	9.89	39.00	29.77	41.14
	Basic and diluted EPS after Exceptional items (Rs.)	13.57	14.91	2.70	39.24	23.35	34.83
Not Annualised							

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th February 2025. The Statutory auditors have carried out a limited review of the consolidated financial results for the quarter and nine months ended 31st December 2024.
2. Exceptional items pertaining to the period / year :
 - (a) Exceptional items credit for the nine months ended 31st December 2024 of Rs.469 lakhs is on account of profit on sale of surplus residential properties and for the quarter and nine months ended 31st December 2023 of Rs. 16331 lakhs is on account of one off VRS (Voluntary Retirement Scheme) cost including other employee dues of Rs. 5537 lakhs. Additionally exceptional items charge for the nine months ended 31st December 2023 also includes profit on sale of surplus residential properties of Rs. 1730 lakhs.
 - (b) Exceptional items charge for the year ended 31st March 2024 of Rs.14361 lakhs is on account of charge of Rs. 16331 lakhs on account of one off VRS (Voluntary Retirement Scheme) cost including other employee dues of Rs. 5537 lakhs and profit on sale of surplus residential properties of Rs. 1970 lakhs.
3. Dividend of Rs. 20329 lakhs has been paid during the current quarter ended 31st December 2024 consequent to the Board of Directors declaring special interim dividend of Rs. 12 per equity share which had been approved by the Board in the meeting held on 29th October 2024.
4. The Group has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

14th February, 2025

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346